Originally published by our sister publication, Specialty Pharmacy Continuum.
By Gina Shaw
The decision by the Centers for Medicare & Medicaid Services (CMS) to cover the controversial Alzheimer’s drug aducanumab-avwa (Aduhelm, Biogen) under a coverage with evidence development policy is “unique” and not likely to be repeated with other drugs, said Tamara Syrek Jensen, JD, the director of the Coverage and Analysis Group in the CMS Center for Clinical Standards and Quality,